225 related articles for article (PubMed ID: 21159063)
1. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin.
Camilleri M
Neurogastroenterol Motil; 2011 Mar; 23(3):193-200. PubMed ID: 21159063
[TBL] [Abstract][Full Text] [Related]
2. LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.
Camilleri M
IDrugs; 2010 Dec; 13(12):921-8. PubMed ID: 21154152
[TBL] [Abstract][Full Text] [Related]
3. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.
Brown PM; Drossman DA; Wood AJ; Cline GA; Frazier KS; Jackson JI; Bronner J; Freiman J; Zambrowicz B; Sands A; Gershon MD
Gastroenterology; 2011 Aug; 141(2):507-16. PubMed ID: 21684281
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB
World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
Shiotani A; Kusunoki H; Ishii M; Imamura H; Manabe N; Kamada T; Hata J; Merchant JL; Haruma K
Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414
[TBL] [Abstract][Full Text] [Related]
6. Targeting serotonin synthesis to treat irritable bowel syndrome.
Tack J; Janssen P; Wouters M; Boeckxstaens G
Gastroenterology; 2011 Aug; 141(2):420-2. PubMed ID: 21703266
[No Abstract] [Full Text] [Related]
7. Abnormalities of mucosal serotonin metabolism and 5-HT
Gunn D; Garsed K; Lam C; Singh G; Lingaya M; Wahl V; Niesler B; Henry A; Hall IP; Whorwell P; Spiller R
Aliment Pharmacol Ther; 2019 Sep; 50(5):538-546. PubMed ID: 31342534
[TBL] [Abstract][Full Text] [Related]
8. Associations of tryptophan hydroxylase gene polymorphisms with irritable bowel syndrome.
Jun S; Kohen R; Cain KC; Jarrett ME; Heitkemper MM
Neurogastroenterol Motil; 2011 Mar; 23(3):233-9, e116. PubMed ID: 21073637
[TBL] [Abstract][Full Text] [Related]
9. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
Rivkin A; Rybalov S
Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract.
Liu Q; Yang Q; Sun W; Vogel P; Heydorn W; Yu XQ; Hu Z; Yu W; Jonas B; Pineda R; Calderon-Gay V; Germann M; O'Neill E; Brommage R; Cullinan E; Platt K; Wilson A; Powell D; Sands A; Zambrowicz B; Shi ZC
J Pharmacol Exp Ther; 2008 Apr; 325(1):47-55. PubMed ID: 18192499
[TBL] [Abstract][Full Text] [Related]
11. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.
Fant RV; Henningfield JE; Cash BD; Dove LS; Covington PS
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1021-1029.e6. PubMed ID: 28167156
[TBL] [Abstract][Full Text] [Related]
12. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome.
Atkinson W; Lockhart S; Whorwell PJ; Keevil B; Houghton LA
Gastroenterology; 2006 Jan; 130(1):34-43. PubMed ID: 16401466
[TBL] [Abstract][Full Text] [Related]
13. A Reduced Tryptophan Diet in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Improves Their Abdominal Symptoms and Their Quality of Life through Reduction of Serotonin Levels and Its Urinary Metabolites.
Chojnacki C; Medrek-Socha M; Blonska A; Zajdel R; Chojnacki J; Poplawski T
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499643
[TBL] [Abstract][Full Text] [Related]
14. Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome.
Katsumata R; Shiotani A; Murao T; Ishii M; Fujita M; Matsumoto H; Haruma K
Intern Med; 2017; 56(9):993-999. PubMed ID: 28458330
[TBL] [Abstract][Full Text] [Related]
15. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
Liu R; Staller K
Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
[TBL] [Abstract][Full Text] [Related]
16. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
17. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
18. [Serum serotonin concentration and urine 5-hydroxyindole acetic acid excretion in patients with irritable bowel syndrome].
Moskwa A; Chojnacki J; Wiśiewska-Jarosińska M; Stec-Michalska K; Szadkowski K; Smigielski J; Chojnacki C
Pol Merkur Lekarski; 2007 May; 22(131):366-8. PubMed ID: 17679369
[TBL] [Abstract][Full Text] [Related]
19. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
Kulke MH; O'Dorisio T; Phan A; Bergsland E; Law L; Banks P; Freiman J; Frazier K; Jackson J; Yao JC; Kvols L; Lapuerta P; Zambrowicz B; Fleming D; Sands A
Endocr Relat Cancer; 2014 Oct; 21(5):705-14. PubMed ID: 25012985
[TBL] [Abstract][Full Text] [Related]
20. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
